Drug Profile
Research programme: Rel protein inhibitors - BioLineRx/Hebrew University of Jerusalem
Alternative Names: EDP 25Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Hebrew University of Jerusalem
- Developer BioLineRx; Hebrew University of Jerusalem
- Class
- Mechanism of Action Bacterial protein inhibitors; Proto-oncogene protein c-rel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Bacterial-infections in Israel
- 27 Sep 2013 Early research is ongoing in Israel
- 28 Sep 2011 Early research in Bacterial infections in Israel (unspecified route)